StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Otezla (apremilast by Quarter

Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide volume growth YoY (%) (%)

QuarterlyAnnual

Amgen Otezla (apremilast: -6.0% in Q2 2026, down 10.0 pts from a year earlier. That is the lowest of the 18 quarters on record here.

Latest, Q2 2026
-6.0%
Period ended Jun 30, 2026
Change on a year earlier
-10.0 pts
4.0% in Q2 2025
History
18 quarters
Since Q2 2021
Sources
18
Documents cited below

Where the Q2 2026 figure comes from

“Otezla ® (apremilast) sales decreased 21% year-over-year to $491 million in the second quarter, primarily driven by 9% lower net selling price and 6% lower volume.”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOtezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide volume growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-6.0%-10.0 ptsForm 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026-2.0%-6.0 ptsForm 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q3 2025Sep 30, 20256.0%+1.0 ptsForm 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 20254.0%+2.0 ptsForm 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 20254.0%–Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 20245.0%+2.0 ptsForm 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 20245.0%+4.0 ptsForm 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20242.0%0.0 ptsForm 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q4 2023Dec 31, 20233.0%-4.0 ptsForm 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 20231.0%-8.0 ptsForm 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 20232.0%-6.0 ptsForm 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 20235.0%-2.0 ptsForm 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20227.0%–Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 20229.0%+2.0 ptsForm 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 20228.0%+3.0 ptsForm 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 20227.0%–Form 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗

Cite this data

StockData. (2026). Amgen Otezla (apremilast (%), quarterly Q2 2021–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-otezla-vol

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.